Introduction:
Swiss obesity start-up SixPeaks Bio AG has announced a US$30m Series A financing led by Versant Ventures and a US$80m partnership with AstraZeneca plc. The collaboration with AstraZeneca aims to co-develop a dual-specific antibody that targets the activin type IIA and B receptors, which block myostatin signaling. This disruption could potentially increase muscle mass and decrease glucose levels, offering a potential treatment for obesity. The global market for obesity treatments is expected to reach US$100bn by 2030. AstraZeneca is entering the obesity market to compete with other pharmaceutical companies like Roche.
- SixPeaks Bio has received US$30m in Series A funding and formed a partnership with AstraZeneca to develop a dual-specific antibody targeting the activin type IIA and B receptors.
- The disruption of myostatin signaling could increase muscle mass and decrease glucose levels, providing a potential treatment for obesity.
- The global market for obesity treatments is projected to reach US$100bn by 2030.
- AstraZeneca is entering the obesity market to compete with other pharmaceutical companies like Roche.
Conclusion:
The partnership between SixPeaks Bio and AstraZeneca represents a significant step into the obesity market. By targeting the activin type IIA and B receptors, the companies aim to disrupt myostatin signaling, which could offer a new potential treatment for obesity. With the market for obesity treatments expected to grow significantly in the coming years, AstraZeneca is positioning itself to compete with other pharmaceutical companies in this space.
